Mark Lebwohl, MD, addressed a common clinical dilemma: selecting appropriate treatment regimens for patients with psoriasis amidst an expanding array of biologics and small-molecule inhibitors. His presentation emphasized the integration of therapeutic strategies tailored to disease severity, comorbidities, and patient preferences. He discussed vaccine management for patients on systemic therapies, perioperative considerations for immunomodulators, and obesity interventions using GLP-1 receptor agonists, which not only support weight loss but also improve psoriasis outcomes. Short-term biologics were highlighted as effective options for guttate psoriasis, while rapid interventions for generalized pustular psoriasis, including IL-36 inhibitors, were underscored as critical to mitigating severe disease progression.
A key focus was the utility of emerging therapies, such as risankizumab and bimekizumab, in achieving high clearance rates even in challenging cases like scalp and nail psoriasis. Dr Lebwohl also explored the management of refractory “mild” psoriasis, advocating for an individualized approach to care that improves patient-reported outcomes, including quality of life. His comprehensive discussion provided actionable insights into optimizing treatment plans to address both common and complex scenarios in psoriasis care.
In the first DermInsider - A Virtual Grand Rounds Series session of the year, join leading experts Dr. Bhutani and Dr. Serota for a dynamic deep dive into one of the most exciting frontiers in psoriatic disease management. Dr. Del Rosso moderates this 45-minute activity that explores the rapidly emerging role of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and their potential impact beyond metabolic disease. Don't miss out on this opportunity to catch up on breakthrough insights and emerging evidence on this hot topic!“We have some really interesting data on the horizon that’s going to hopefully help more providers feel confident about using [GLP-1] medications in conjunction with their psoriasis medications that they are used to using.” – Tina Bhutani, MD MASBest of FC25: GLP-1RAs in Psoriasis – Catching Up on The ScienceThis activity is supported by an educational grant from Lilly.
Got a few minutes? Join our expert faculty for their rapid-fire tips on getting started with GLP-1 receptor agonists for patients with psoriasis and obesity.“When we are treating patients with obesity and psoriasis in weight management, really focus on the health gains. It’s not about what people are losing, it’s about what they are gaining in this process.” – Angela Fitch, MDPlease visit the “Educational Resources” page to access the handouts developed by faculty on GLP's in psoriatic disease mentioned in this activity.This activity is supported by an educational grant from Lilly.
In this 20-minute Seminar in Depth from the 2025 Fall Clinical Dermatology Conference, the faculty explore what differentiates TYK2 inhibitors from traditional JAK inhibitors, as well as how to identify patients with psoriasis who may benefit from oral small molecule therapy.“When thinking about a medication, you need to take a number of things into consideration: location of disease, disease severity, and age. Age plays a big role when I think about what medication I’m going to choose for a patient – Are they of child-bearing age? Are they young and they live in group housing or a dorm?” – Benjamin Lockshin, MDFC25: Encapsulating Progress With New and Emerging TYK2 Inhibitors for Psoriasis: An Online ActivityThis activity is supported by an educational grant from Bristol Myers Squibb.